Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors
DNA mismatch repair deficiency has been identified as a biomarker that strongly correlates with tumor response to anti-programmed cell death protein-1 (PD-1) checkpoint blockade therapy in the metastatic setting. In a promising Phase 2 study published…